A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00219063

Enrollment

844

Registered

2005-09-22

Start date

2005-02-28

Completion date

2006-03-31

Last updated

2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, aliskiren, blood pressure, Ramipril, hydrochlorothiazide

Brief summary

To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.

Interventions

DRUGaliskiren

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with essential hypertension * Patients who are eligible and able to participate in the study

Exclusion criteria

* Severe hypertension * History or evidence of a secondary form of hypertension * History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion

Design outcomes

Primary

Measure	Time frame
Change from baseline in diastolic blood pressure after 26 weeks	—

Secondary

Measure	Time frame
Change from baseline in systolic blood pressure after 26 weeks	—
Change from baseline in diastolic blood pressure after 6 weeks and 12 weeks	—
Change from baseline in systolic blood pressure after 6 weeks and 12 weeks	—
Blood pressure control target of < 140/90 mmHg after 6, 12, and 26 weeks	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026